Pharmaceutical company Evoke Pharma Inc (NASDAQ:EVOK) announced on Thursday that it has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for its patent application related to GIMOTI (metoclopramide) nasal spray.
GIMOTI is the first FDA-approved nasal formulation of metoclopramide available in the United States.
When issued, the patent will cover the intranasal pharmaceutical composition of GIMOTI and will be set to expire in 2029.
According to Evoke Pharma, GIMOTI has demonstrated a meaningful reduction in utilization of healthcare resources and presents a novel solution to diabetic gastroparesis treatment by delivering a non-oral dose of metoclopramide to relieve symptoms in adults. GIMOTI has been commercially available in the United States since 2020 and is currently prescribed by over 1,000 healthcare providers nationwide.
Calliditas Therapeutics' setanaxib receives US FDA orphan drug designation
Evommune signs strategic collaboration with Maruho Co
IDEAYA Biosciences' IDE161 receives US FDA fast track designation
Melt Pharmaceuticals enters exclusive agreement with Catalent for Zydis fast-dissolve tech
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Sanofi granted Priority Review for EoE treatment in young children
Valneva secures USD32m IXIARO vaccine contract with US DoD
Sanofi's ALTUVIIIO gains Japanese approval as haemophilia A factor VIII therapy
Seagen and Astellas Pharma report positive outcomes in advanced bladder cancer trial
Mabwell's 9MW3011 receives US FDA Fast Track Designation
89bio receives FDA Breakthrough Therapy Designation for pegozafermin in NASH treatment
Hepagene Therapeutics' HPG7233 IND application receives US FDA approval
Pulmatrix PUR3100 investigational new drug application receives US FDA acceptance
BeiGene regains full rights to anti-PD-1 antibody TEVIMBRA (tislelizumab) from Novartis